Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANL NASDAQ:CUE NASDAQ:GNTA NASDAQ:LEXX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANLAdlai Nortye$1.67-1.4%$1.55$1.10▼$3.89$61.48M-0.9511,428 shs1,136 shsCUECue Biopharma$0.83+1.8%$0.77$0.45▼$1.99$63.48M1.53256,508 shs172,800 shsGNTAGenenta Science$3.51-4.4%$3.60$2.74▼$7.28$64.20M0.6214,894 shs3,517 shsLEXXLexaria Bioscience$0.79+0.9%$0.89$0.77▼$4.38$15.51M0.79140,884 shs151,535 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANLAdlai Nortye-0.29%-3.98%+8.40%-8.65%-43.67%CUECue Biopharma+0.37%+2.71%-9.74%+22.68%-10.35%GNTAGenenta Science+1.53%+1.50%-8.58%-19.54%-15.83%LEXXLexaria Bioscience-1.69%-1.64%-18.98%-28.55%-76.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANLAdlai Nortye1.4187 of 5 stars3.03.00.00.01.90.00.0CUECue Biopharma2.6564 of 5 stars0.05.00.04.72.90.80.6GNTAGenenta Science1.9139 of 5 stars3.53.00.00.00.61.70.0LEXXLexaria Bioscience3.7005 of 5 stars3.55.00.00.02.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANLAdlai Nortye 2.00Hold$9.00440.22% UpsideCUECue Biopharma 0.00N/AN/AN/AGNTAGenenta Science 3.00Buy$25.00617.57% UpsideLEXXLexaria Bioscience 3.00Buy$4.00396.28% UpsideCurrent Analyst Ratings BreakdownLatest LEXX, GNTA, CUE, and ANL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.007/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.006/2/2025ANLAdlai NortyeHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANLAdlai Nortye$5M12.30N/AN/A$0.69 per share2.41CUECue Biopharma$8.29M7.50N/AN/A$0.24 per share3.37GNTAGenenta ScienceN/AN/AN/AN/A$0.74 per shareN/ALEXXLexaria Bioscience$460K34.27N/AN/A$0.48 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANLAdlai Nortye-$51.87MN/A0.00N/AN/AN/AN/AN/AN/ACUECue Biopharma-$40.67M-$0.56N/AN/AN/A-469.35%-230.13%-111.16%N/AGNTAGenenta Science-$9.64MN/A0.00N/AN/AN/AN/AN/AN/ALEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/ALatest LEXX, GNTA, CUE, and ANL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025CUECue Biopharma-$0.13-$0.09+$0.04-$0.09$2.00 million$2.95 million7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANLAdlai NortyeN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AGNTAGenenta ScienceN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANLAdlai Nortye0.021.411.41CUECue Biopharma0.011.601.60GNTAGenenta ScienceN/A6.896.89LEXXLexaria BioscienceN/A3.903.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANLAdlai Nortye35.21%CUECue Biopharma35.04%GNTAGenenta Science15.13%LEXXLexaria Bioscience13.06%Insider OwnershipCompanyInsider OwnershipANLAdlai NortyeN/ACUECue Biopharma10.78%GNTAGenenta Science28.99%LEXXLexaria Bioscience26.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANLAdlai Nortye12736.90 millionN/ANot OptionableCUECue Biopharma6076.85 million68.56 millionOptionableGNTAGenenta Science718.29 million12.99 millionNot OptionableLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableLEXX, GNTA, CUE, and ANL HeadlinesRecent News About These CompaniesLexaria Bioscience stock rises after completion of GLP-1 study milestoneAugust 14, 2025 | investing.comLexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 studyAugust 14, 2025 | msn.comLexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" MilestoneAugust 14, 2025 | accessnewswire.comALexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" MilestoneAugust 14, 2025 | thenewswire.comTGLP-1 "Arms Race" Broadens to Include Dozens of CompaniesAugust 6, 2025 | accessnewswire.comALEXX: Third Quarter ResultsJuly 31, 2025 | finance.yahoo.comInsider Buying: Lexaria Bioscience Corp. (NASDAQ:LEXX) Director Buys 11,900 Shares of StockJuly 31, 2025 | insidertrades.comLexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 StudyJuly 28, 2025 | accessnewswire.comALexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 StudyJuly 28, 2025 | thenewswire.comTLexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-IndustryJuly 23, 2025 | accessnewswire.comALexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-IndustryJuly 23, 2025 | thenewswire.comTLEXX - Lexaria Bioscience Corp Dividends - MorningstarJuly 12, 2025 | morningstar.comMLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | thenewswire.comTLexaria Reaches Patent Milestone - 50 Patents Now Granted WorldwideJune 23, 2025 | accessnewswire.comALexaria Bioscience announces completion of GLP-1-H25-5 studyJune 12, 2025 | finance.yahoo.comLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | thenewswire.comTLexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered CapsuleJune 11, 2025 | accessnewswire.comALexaria Bioscience Corp.: Lexaria Attending BIO International ConventionJune 5, 2025 | finanznachrichten.deLexaria Attending BIO International ConventionJune 5, 2025 | thenewswire.comTLexaria Attending BIO International ConventionJune 5, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeLEXX, GNTA, CUE, and ANL Company DescriptionsAdlai Nortye NASDAQ:ANL$1.67 -0.02 (-1.42%) Closing price 03:57 PM EasternExtended Trading$1.65 -0.02 (-0.96%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.Cue Biopharma NASDAQ:CUE$0.83 +0.01 (+1.80%) Closing price 04:00 PM EasternExtended Trading$0.83 +0.00 (+0.48%) As of 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Genenta Science NASDAQ:GNTA$3.46 -0.21 (-5.69%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.Lexaria Bioscience NASDAQ:LEXX$0.79 +0.01 (+0.88%) Closing price 04:00 PM EasternExtended Trading$0.81 +0.01 (+1.66%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access